Veracyte, Inc. (VCYT) stock
VCYTNasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 16/3034% below fair value
$24.23+0.22 (+0.92%)
Close on Nov 17, 2026Market cap $1.95BP/E 17.3Yield –
Veracyte enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
Veracyte's enterprise value was $1.72B on Nov 11, 2026, against $3.42B a year earlier. Over the last 5 years it ranged from $1.03B to $4.42B, with a median of $1.81B.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | $1.72B | -42.9% |
| 2025 | Dec 31, 2025 | $3.01B | +7.8% |
| 2024 | Dec 31, 2024 | $2.79B | +54.8% |
| 2023 | Dec 29, 2023 | $1.80B | +17.7% |
| 2022 | Dec 30, 2022 | $1.53B | -44.5% |
| 2021 | Dec 31, 2021 | $2.76B | +11.2% |
| 2020 | Dec 31, 2020 | $2.48B | +112.8% |
| 2019 | Dec 31, 2019 | $1.17B | +155.6% |
| 2018 | Dec 31, 2018 | $456.68M | +122.7% |
| 2017 | Dec 29, 2017 | $205.07M | -2.1% |
| 2016 | Dec 30, 2016 | $209.45M | +32.5% |
| 2015 | Dec 31, 2015 | $158.02M | -11.4% |
| 2014 | Dec 31, 2014 | $178.26M | +4555.1% |
| 2013 | Dec 31, 2013 | $3.83M | – |
See a number that looks wrong?